Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
International Journal of Radiation Oncology, Biology, Physics|November 1, 2023
SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient SelectionAhsan S Farooqi, Alison K Yoder, Heather Y Lin, et al.
Annals of Surgical Oncology|May 26, 2026
The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.
Cell Reports|April 22, 2014
Isolation and molecular characterization of circulating melanoma cellsXi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Nature|November 6, 2012
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin backgroundDevarati Mitra, Xi Luo, Ann Morgan, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
The Lancet. Oncology|November 7, 2022
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trialB Ashleigh Guadagnolo, Roland L Bassett, Devarati Mitra, et al.
Frontiers in Immunology|May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experienceMadeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
Pageof 7